SCHEMBL5841789

SCHEMBL5841789

CCn1c2ccccc2c2cc(NC(=O)C3CC(=O)N(c4ccc(C)cc4)C3)ccc21

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.58
THRB P10828 1/20 0.58
ROCK2 O75116 1/20 0.56
ROCK1 Q13464 1/20 0.56
POLB P06746 1/20 0.55
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
TP53 P04637 1/20 0.54
NPSR1 Q6W5P4 1/20 0.53
MAPT P10636 4/20 0.52
LMNA P02545 3/20 0.52
TSHR P16473 2/20 0.52
KDM4E B2RXH2 2/20 0.52
MAPK1 P28482 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
RECQL P46063 1/20 0.52
USP2 O75604 1/20 0.52
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5842465 0.93 NPSR1 (0.56) SMN1; SMN2ROCK2ROCK1TDP1L3MBTL1
SCHEMBL27617658 0.92 MEN1 (0.62) SMN1; SMN2POLBL3MBTL1NPSR1MAPT
SCHEMBL5842953 0.90 TP53 (0.61) SMN1; SMN2POLBL3MBTL1TP53NPSR1
SCHEMBL5843062 0.86 MEN1 (0.55) SMN1; SMN2L3MBTL1NPSR1MAPTLMNA
SCHEMBL5841644 0.86 MAPT (0.61) SMN1; SMN2POLBTP53NPSR1MAPT
SCHEMBL5844481 0.86 NPY5R (0.54) SMN1; SMN2POLBL3MBTL1NPSR1MAPT
SCHEMBL6611383 0.85 MAPT (0.51) SMN1; SMN2TP53NPSR1MAPTLMNA
SCHEMBL5842506 0.83 MAPT (0.53) SMN1; SMN2POLBL3MBTL1NPSR1MAPT
SCHEMBL5842206 0.83 MAPT (0.53) SMN1; SMN2POLBL3MBTL1NPSR1MAPT
SCHEMBL5842917 0.83 MAPT (0.53) SMN1; SMN2POLBL3MBTL1NPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US claimed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US claimed
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R SMN1; SMN2 3678/4885THRB 310/4885ROCK2 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.